| | | No, I didn't go short. Lost interest completely. I've followed Frost since his days with Key Pharmaceuticals and am all too familiar with these types of swings. I think Ivax is probably a good long term buy, but wouldn't own much as a percentage of the portfolio because Frost's record isn't great, don't think he's proven that he can really manage a company for long term growth such as other generics BRL, AZA, TEVA or even MYL despite its recent setback. He has a tendency to rely on single drug home runs and when things fizzle so does the stock price until he can develop another. This doesn't make good predictable earnings growth. While Taxol-generic might work and make money for a while, according to Ivax's own investor relations and I quote from my conversation with him: "No one is going to make much money from these taxol drugs because of the competition." You can read my posts from way back on the subject -- some kinda crazy but some to the point. Good luck, Jackson |
|
